Anti-Infection Management: Resistance, Resistant and Persistent

Overview of Antimicrobial Resistance (AMR)

Epidemiological Burden & Statistics

• Antimicrobial utilization across hospital and community settings represents a significant driver of selective pressures:

  • $20\%$ of newborns are exposed to maternal antibiotics during the perinatal period.

  • $13\%$ of patients attending Accident & Emergency (A&E) departments are prescribed antibiotics.

  • $33.3\%$ (one-third) of all hospital in-patients are receiving active antibiotic therapy at any given point in time.

Definition and Consequences of AMR

• Antimicrobial Resistance (AMR) refers to the acquired or intrinsic ability of microorganisms to survive exposure to therapeutic concentrations of antimicrobial agents (e.g., penicillin) that would otherwise inhibit their growth or kill them.

• Clinical and Public Health Consequences:

  • Uncomplicated, routine infections require prolonged hospitalizations and escalation to second- or third-line therapeutics.

  • Severe systemic infections are associated with markedly increased patient morbidity and mortality.

  • The progressive emergence of multi-drug resistant (MDR), extensively drug-resistant (XDR), and pan-drug resistant (PDR) strains threatens to create clinical scenarios with zero available treatment options.

Classification of Antimicrobial Resistance

Resistance is broadly categorized into Clinical Resistance and Microbiological Resistance:

• Clinical Resistance:

  • Occurs when an antimicrobial agent fails to achieve adequate therapeutic levels within the target infection site, tissue, or body fluid, despite the microorganism exhibiting susceptibility in vitro.

  • Driven by pharmacokinetic/pharmacodynamic (PK/PD) failure, poor tissue penetration, drug degradation, or host anatomical barriers.

• Microbiological Resistance:

  • Occurs when the microorganism possesses a specific biological mechanism that reduces susceptibility relative to wild-type strains.

  • Subdivided into three distinct operational types:

  1. Intrinsic (Primary) Resistance:

     • Natural, innate structural or functional features characteristic of an entire microbial species or genus prior to antibiotic exposure.

     • Examples include the lack of a peptidoglycan cell wall in Mycoplasma species or the impermeable outer membrane of Gram-negative bacilli to bulky hydrophobic molecules.

  2. Adaptive Resistance:

     • Transient, reversible alterations in gene or protein expression triggered by environmental stressors, sub-inhibitory antibiotic levels, or specific growth conditions.

     • Frequently regulated by epigenetic changes, including DNA or RNA methylation and histone modification.

  3. Acquired (Secondary) Resistance:

     • Stable, heritable alterations in microbial genetics resulting from chromosomal mutations or horizontal transfer of foreign resistance genes.

Mechanisms of Resistance Across Categories

Antimicrobial resistance mechanisms span all drug classes and operate through distinct physiological pathways:

• Intrinsic Mechanisms:

  • Constitutive expression of active efflux pumps.

  • Reduced outer membrane permeability.

  • Reduced binding affinity of target proteins (e.g., altered Penicillin-Binding Proteins [PBPs]).

  • Complete innate absence of the biochemical drug target.

• Adaptive Mechanisms:

  • Epigenetic modifications (DNA/RNA methylation, histone modifications) upregulating efflux systems or downregulating porin channel synthesis.

  • Formation of Persister Cells: Metabolically dormant phenotypic variants within a genetically susceptible population that survive lethal antibiotic concentrations without carrying genetic mutations.

  • Formation of Biofilms: Structured communities of microorganisms encapsulated within a self-produced matrix of extracellular polymeric substances (EPS). Biofilms restrict antibiotic diffusion, create metabolic gradients (depleting $\text{O}_2$ and nutrients), and facilitate quorum sensing (QS).

• Acquired Mechanisms:

  • Horizontal Gene Transfer (HGT):

  1. Conjugation: Direct cell-to-cell transfer of plasmid DNA via a sex pilus.

  2. Transduction: Bacteriophage-mediated transfer of bacterial DNA segments between host bacteria.

  3. Transformation: Direct uptake and chromosomal integration of free extracellular DNA fragments released from lysed dead bacteria.

  • Genetic Mutations: Chromosomal point mutations, insertions, or deletions causing:

  • Enzymatic inactivation (degrading enzymes such as $\beta$-lactamases, or modifying enzymes like aminoglycoside-modifying enzymes).

  • Modification of cell wall components or drug targets (e.g., ribosomal mutations, DNA gyrase mutations).

  • Upregulation of multidrug efflux pumps or deletion/downregulation of porin channels.

Phenotypic Mechanisms of Resistance

• Drug Indifference:

  • Occurs when bacteria exist in a non-replicating or resting state, as bactericidal agents targeting cell wall synthesis (e.g., $\beta$-lactams) act predominantly on actively dividing cells.

  • High bacterial inoculum effect ("overwhelming bacterial load") where the sheer cell density overwhelms local drug availability.

• Persisters:

  • Phenotypic subpopulations capable of surviving high antibiotic challenges through metabolic shutdown, re-establishing population growth upon drug withdrawal.

• Biofilms:

  • Protective physical barrier combined with steep micro-environmental gradients of oxygen, nutrients, and $\text{pH}$. Biofilms coordinate group resistance behaviors via quorum sensing (QS).

• Changes in Bacterial Permeability:

  • Dynamic structural alterations in lipopolysaccharide (LPS), porin expression, release of outer membrane vesicles (OMVs), and recruitment of multidrug efflux pumps driven by environmental temperature, reactive oxygen species (ROS), metabolic stress, and biochemical inducers.

Major Resistant Pathogens

Microbial classification into Gram-positive and Gram-negative species highlights clinical resistance profiles:

• Gram-Positive Cocci:

  • Staphylococcus aureus: Methicillin-Resistant Staphylococcus aureus (MRSA) demonstrates universal resistance to classical $\beta$-lactams through altered target acquisition.

  • Streptococcus spp.: Penicillin-resistant Streptococcus pneumoniae.

  • Enterococcus spp.: Vancomycin-Resistant Enterococcus (VRE) exhibits glycopeptide resistance via target modification ($\text{D-Ala-D-Ala}$ to $\text{D-Ala-D-Lac}$ or $\text{D-Ala-D-Ser}$).

• Gram-Positive Rods:

  • Corynebacterium spp., Listeria monocytogenes, Clostridium difficile(toxin-producing, anaerobe causing pseudomembranous colitis).

• Gram-Negative Cocci:

  • Neisseria gonorrhoeae (Gonococcus).

• Gram-Negative Rods (Enterobacterales and Non-Fermenters):

  • Strains include Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia, and Helicobacter pylori.

  • ESBL-producing Enterobacterales: Confer resistance to penicillins, 1st, 2nd, 3rd, and 4th generation cephalosporins, and piperacillin-tazobactam (Tazocin).

  • Carbapenem-Resistant Enterobacteriaceae (CRE): Strains bearing carbapenemase genes (e.g., VIM, NDM-1, KPC-2, OXA-48) conferring resistance to penicillins, cephalosporins, carbapenems, and multiple non-$\beta$-lactam drug classes.

Beta-Lactams and Beta-Lactamases

Mechanism of Action of Beta-Lactam Antibiotics

• $\beta$-Lactam compounds constitute the most widely prescribed class of bactericidal antimicrobials.

• Molecular Target: Penicillin-Binding Proteins (PBPs), specifically transpeptidase domain subunits that catalyze peptide cross-linking of adjacent peptidoglycan polymer chains in the bacterial cell wall.

• Mechanism:

  • The highly reactive four-membered $\beta$-lactam ring structural analog binds covalently to the active site serine residue of PBPs.

  • Inhibition of transpeptidation halts peptidoglycan synthesis.

  • Structural instability leads to uncoordinated activity of bacterial cell wall autolytic enzymes (autolysins), resulting in osmotic lysis and cell death.

Mechanisms of Beta-Lactamase Resistance

• In Gram-negative bacteria, resistance to $\beta$-lactams is predominantly mediated by $\beta$-lactamases.

• Enzymatic Action: Hydrolytic enzymes that cleave the amide bond of the four-membered $\beta$-lactam ring, converting the antibiotic into an inactive derivative unable to bind PBPs.

• Additional Contributing Resistance Mechanisms:

  • Target (PBP) Modification: Acquisition of foreign PBPs with reduced binding affinity (e.g., PBP2a in MRSA encoded by the mecA gene; PBP2x/2b in S. pneumoniae).

  • Porin Loss/Modification: Downregulation or mutation of outer membrane porin proteins (e.g., OprD in Pseudomonas aeruginosa), limiting drug entry to the periplasmic space.

  • Efflux Pump Hyperexpression: Active transport of $\beta$-lactams out of the periplasm (e.g., MexAB-OprM system in P. aeruginosa).

Cephalosporin Generations and Evolution

Cephalosporins are derived from Cephalosporin C, containing a core cephem nucleus ($\beta$-lactam ring fused to a dihydrothiazine ring) modified at the $\text{C7}$ and $\text{C3}$ side chains:

• Generation 1: Cephalothin, Cephalexin. Active against Gram-positive cocci; vulnerable to $\beta$-lactamases.

• Generation 2: Cefoxitin (cephamycin), Cefuroxime. Enhanced stability against early $\beta$-lactamases; improved Gram-negative coverage.

• Generation 3: Ceftazidime, Cefotaxime, Ceftriaxone. Broad Gram-negative coverage; susceptible to degradation by ESBLs.

• Generation 4: Cefpirome, Cefepime. Zwitterionic structure providing rapid outer membrane penetration and stability against chromosomal AmpC $\beta$-lactamases.

• Anti-Pseudomonal Cephalosporins: Ceftolozane (co-formulated with tazobactam).

• Anti-MRSA Cephalosporins: Ceftobiprole, Ceftaroline (engineered with high binding affinity for PBP2a).

The Global Antibiotic Crisis & Discovery Void

• Epidemiological Trends in Carbapenemase-Producing Gram-Negative Bacilli:

  • In the UK, annual confirmed cases of carbapenemase-producing isolates increased from near zero in 2007 to over 3,000 confirmed isolates by 2016.

Ambler Classification of Beta-Lactamases

$\beta$-Lactamases in Enterobacterales are classified according to primary amino acid sequence homology into four distinct Ambler classes:

1. Ambler Class A (Serine $\beta$-lactamases):

   • Narrow-spectrum Penicillinases: Early TEM-1, TEM-2, SHV-1.

   • Extended-Spectrum $\beta$-lactamases (ESBLs): Variants of TEM, SHV, and widespread CTX-M enzymes.

   • Serine Carbapenemases: KPC (Klebsiella pneumoniae carbapenemase), GES, IMI, NMC-A.

2. Ambler Class B (Metallo-$\beta$-lactamases - MBLs):

   • Require zinc ion cofactor ($\text{Zn}^{2+}$) for catalysis; hydrolyze penicillins, cephalosporins, and carbapenems, but spare aztreonam.

   • Includes VIM, IMP, NDM (New Delhi metallo-$\beta$-lactamase), GIM.

3. Ambler Class C (Cephalosporinases):

   • Chromosomally encoded or plasmid-mediated AmpC $\beta$-lactamases.

   • Resist classical $\beta$-lactamase inhibitors (clavulanic acid, tazobactam).

4. Ambler Class D (Oxacillinases / OXA-type):

   • Serine-based enzymes with variable hydrolysis spectrums.

   • Includes narrow-spectrum OXA, ESBL-type OXA, and carbapenemases (OXA-48, OXA-23, OXA-24/40, OXA-58).

EUCAST Definition & Characteristics of ESBLs

• According to the European Committee on Antimicrobial Susceptibility Testing (EUCAST):

  • Detection of ESBL resistance mechanisms is not required for clinical antimicrobial susceptibility categorization (reporting is based directly on MIC testing).

  • Detection is required for infection control and public health surveillance purposes.

• Inhibitor Profile: Most ESBLs belong to Ambler Class A and are inhibited by classical $\beta$-lactamase inhibitors (clavulanic acid, sulbactam, tazobactam) and diazabicyclooctanone non-$\beta$-lactam inhibitors (avibactam).

Mobile Genetic Elements (MGEs)

ESBL and carbapenemase genes are encoded on highly transmissible mobile genetic structures that facilitate horizontal dissemination across bacterial strains and species:

• Transposons: DNA sequences flanked by Inverted Repeats (IR) containing transposase (tnpA) and recombinase/resolvase (tnpR) genes along with resistance markers (e.g., bla genes).

• Integrons: Genetic site-specific recombination platforms consisting of a 5'-conserved segment encoding an integrase gene (intl1), an attachment site (attI), promoter regions ($\text{P}$), variable resistance gene cassettes flanked by attC sites, and a 3'-conserved segment encoding resistance genes like sulfonamide resistance (sul1).

• Plasmids: Circular, self-replicating extrachromosomal double-stranded DNA molecules harbouring clusters of resistance determinants (e.g., sul2, mphA, mphR, bla_TEM).

Management of Complex & Difficult-to-Treat Infections

The Host-Drug-Pathogen Triad

Managing complex clinical infections requires balancing relationships across three domains:

• Host – Drug Interactions:

  • Pharmacokinetics (PK): Absorption, distribution, metabolism, and excretion (ADME) determining drug exposure.

  • Toxicity: Off-target adverse effects on organ systems.

• Drug – Bacteria Interactions:

  • Pharmacodynamics (PD): Minimum inhibitory concentration (MIC), bactericidal killing kinetics ($\text{C}_{\max}/\text{MIC}$, $\text{AUC}/\text{MIC}$, Time above MIC [$\%T>\text{MIC}$]).

  • Resistance: Development of microbiological resistance mechanisms.

• Host – Bacteria Interactions:

  • Infection: Pathogenicity, tissue destruction, and virulence factors.

  • Host Defence: Innate and adaptive immune clearance.

Case Examples: Cellulitis vs. Prosthetic Joint Infection

Two clinical vignettes illustrate how anatomical site and foreign material alter management strategy despite identical bacterial isolates and in vitro susceptibility profiles:

• Case Study 1 (Uncomplicated Tissue Infection):

  • Patient: 66 y/o male with HTN, asthma. On amlodipine 5mg OD, Symbicort 200/6 MART.

  • Presentation: Right leg abrasion while plastering; 1-week history of localized erythema, heat, pain, and tenderness.

  • Microbiology: Wound swab grew Staphylococcus aureus susceptible to clindamycin, erythromycin, co-trimoxazole, vancomycin, doxycycline, and flucloxacillin.

  • Diagnosis: Cellulitis.

  • Management: Flucloxacillin 500mg PO q6h for 7 days.

• Case Study 2 (Complex Foreign-Material Device Infection):

  • Patient: 66 y/o male with identical past history and drug history; right prosthetic knee replacement (2018).

  • Presentation: Right knee hot and swollen over the last week.

  • Microbiology: Blood cultures positive for Staphylococcus aureus with identical susceptibility profile (susceptible to flucloxacillin, vancomycin, etc.).

  • Diagnosis: Suspected Prosthetic Joint Infection (PJI).

  • Management: Flucloxacillin 2g IV q6h for an extended overall antibiotic duration of 12 weeks.

Bone and Joint Infections

Spectrum of Conditions

Bone and joint infections include osteomyelitis, discitis, septic arthritis, prosthetic joint infection (hip and knee), and diabetic foot osteomyelitis.

Pathogenesis of Osteomyelitis

Osteomyelitis is an inflammatory destruction of bone caused by an infectious pathogen, involving the marrow, cortex, periosteum, and surrounding soft tissues:

1. Local Contiguous Spread: Secondary to direct trauma, orthopedic bone surgery, or joint replacement. The presence of a foreign body implant creates a focal site for bacterial adherence and biofilm establishment.

2. Vascular Insufficiency: Predominantly seen in patients with long-standing diabetes mellitus. Begins as a soft-tissue foot ulcer that extends contiguously to underlying bone. Compounded by localized soft-tissue ischemia and peripheral motor, sensory, and autonomic neuropathy.

3. Haematogenous Osteomyelitis: Occurs predominantly in prepubertal children and elderly individuals. Caused by bacterial seeding originating from transient bacteremia into slightly injured or highly vascularized bone metaphyses.

Osteomyelitis Treatment Principles

• Single-agent antimicrobial therapy is typically adequate for native osteomyelitis, whereas prosthetic joint infections require combination therapy including rifampicin to clear biofilm-associated resting bacteria.

• Standard treatment duration is 4 to 6 weeks, initiated via the intravenous route.

• Three core considerations: Antimicrobial Penetration, Diagnostic Certainty, and Duration of Therapy.

Prosthetic Joint Infection (PJI) Management

• Source Control: Surgical intervention is mandatory to achieve open or percutaneous drainage and radical debridement of infected periprosthetic tissue.

• Surgical Decision Tree:

  • Debridement and Implant Retention (DAIR): Indicated if symptom duration is $<3\text{ weeks}$ OR joint age is $<30\text{ days}$, provided the prosthesis is well-fixed, there is an absence of a sinus tract, and the pathogen is susceptible to oral agents.

  • One-Stage or Two-Stage Revision / Removal of Prosthesis: Indicated if symptoms exceed $3\text{ weeks}$, joint age is $\ge 30\text{ days}$, a sinus tract is present, or the implant is loose.

Central Nervous System (CNS) Infections

Differential and Presentation

• CNS infections include bacterial or viral meningitis, viral encephalitis, brain abscess, epidural abscess, ventriculitis, and prion encephalopathies.

• Clinical Symptom Matrix (Encephalitis vs. Meningitis):

Blood-Brain Barrier (BBB) & Drug Penetration

• The Blood-Brain Barrier (BBB) limits antimicrobial diffusion into CSF and brain parenchyma via brain capillary endothelial cells linked by tight junctions.

• Factors Affecting BBB Penetration:

  • Passive diffusion is restricted to small, uncharged, lipophilic molecules with a molecular weight $<400\text{--}600\,\text{Da}$.

  • Active meningeal inflammation loosens tight junction integrity, enhancing drug penetration.